Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, South Africa, and Lesotho. In 2024, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids, and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased. However, despite being available worldwide, not all adults have access to antiretroviral drugs. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

The average for 2022 based on 135 countries was 1.66 percent. The highest value was in Swaziland: 25.9 percent and the lowest value was in Afghanistan: 0.1 percent. The indicator is available from 1990 to 2022. Below is a chart for all countries where data are available.

Dataset Overview

The dataset provides a comprehensive look at HIV/AIDS adult prevalence rates, the number of people living with HIV, and annual deaths across different countries. It is based on publicly available data sources such as the CIA World Factbook, UNAIDS AIDS Info, and other global health organizations. The dataset primarily focuses on adult HIV prevalence (ages 15–49) and includes estimates from recent years (e.g., 2023–2024).

Data Science Applications

This dataset can be used for: - Epidemiological Analysis: Understanding the regional distribution of HIV/AIDS and identifying high-prevalence areas. - Predictive Modeling: Developing machine learning models to predict HIV prevalence trends or identify risk factors. - Resource Allocation: Informing policymakers about regions requiring urgent intervention or resource allocation. - Health Outcome Monitoring: Tracking progress in combating HIV/AIDS over time. - Social Determinants Research: Analyzing the relationship between socio-economic factors and HIV prevalence.

Column Descriptors

1. Country/Region: The geographical area being analyzed.
2. Adult Prevalence (%): Percentage of adults aged 15–49 living with HIV.
3. Number of People with HIV/AIDS: Absolute count of individuals living with HIV in the region.
4. Annual Deaths from HIV/AIDS: Number of deaths attributed to HIV/AIDS annually.
5. Year of Estimate: The year when the data was collected or estimated.

Ethically Mined Data

The dataset is ethically sourced from publicly available and credible platforms such as the CIA World Factbook, UNAIDS, and WHO. These organizations ensure transparency and ethical standards in data collection, protecting individual privacy while providing aggregate statistics for research purposes.

Acknowledgments

1. Data Source Platforms:
   • CIA World Factbook
   • UNAIDS AIDS Info
   • WHO Global Health Observatory
2. Dataset Visualization Image:
   • Created using DALL-E 3 for illustrative purposes.
3. Research Support:
   • Contributions from platforms like ResearchGate, NIMH, and others for insights into data science applications in HIV research.

This dataset serves as a valuable tool for researchers, policymakers, and public health professionals in addressing the global challenge of HIV/AIDS.

The total number of people globally living with HIV has increased from **** million people in 2000 to **** million people in 2024. However, the total number of new HIV infections has decreased from *** million in 2000 to *** million in 2024. It has become easier for those infected with HIV to live longer lives. Death rates for HIV-positive people are decreasing, mostly due to antiretroviral drugs that have turned the infection into a chronic disease. Nevertheless, those with HIV are at a higher risk for conditions such as liver disease, heart disease, and cancer. Medication for HIV has become more widespread and has made HIV a more manageable condition. However, medicine is not widely accessible in the developing world, and treatment is still lacking. In Eswatini, around ** percent of all people between 15 and 49 years are living with HIV, while the percentage is around ** in South Africa. HIV infections are still especially widespread in Eastern and Southern Africa, with **** million people living with the condition in 2024. In the same year, there were around *** million people in Latin America living with HIV.

Global HIV Incidence by Country, 2023 Discover more data with ReportLinker!

In 2024, it was estimated that around ** percent of Botswana's population aged 15-49 years was infected with HIV. This statistic shows the 20 countries with the highest prevalence of HIV worldwide as of 2024.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

Source: The World Bank Last Updated: 10/26/2023 Database: World Development Indicators Series: Prevalence of HIV, total (% of population ages 15-49) Adults (ages 15+) and children (ages 0-14) newly infected with HIV Adults (ages 15-49) newly infected with HIV Antiretroviral therapy coverage (% of people living with HIV) Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) Children (0-14) living with HIV Children (ages 0-14) newly infected with HIV Incidence of HIV, ages 15-24 (per 1,000 uninfected population ages 15-24) Incidence of HIV, ages 15-49 (per 1,000 uninfected population ages 15-49) Incidence of HIV, all (per 1,000 uninfected population) Prevalence of HIV, female (% ages 15-24) Prevalence of HIV, male (% ages 15-24) Women's share of population ages 15+ living with HIV (%) Young people (ages 15-24) newly infected with HIV

https://datacatalog.worldbank.org/public-licenses#cc-by

This statistic describes some of the key figures on the global HIV/AIDS epidemic as of 2024. For 2024, it was estimated that there were a total of 40.8 million people living with HIV/AIDS around the world. Around 31.6 million of these people had access to antiretroviral therapy treatment.

In 2024, around *** percent of Thailand's population aged between 15 and 49 years was infected with HIV. This statistic describes the HIV prevalence among the adult population of select countries worldwide as of 2024.

Global HIV-AIDS Mortality by Country, 2023 Discover more data with ReportLinker!

Malawi MW: Antiretroviral Therapy Coverage: % of People Living with HIV data was reported at 71.000 % in 2017. This records an increase from the previous number of 66.000 % for 2016. Malawi MW: Antiretroviral Therapy Coverage: % of People Living with HIV data is updated yearly, averaging 20.500 % from Dec 2000 (Median) to 2017, with 18 observations. The data reached an all-time high of 71.000 % in 2017 and a record low of 0.000 % in 2003. Malawi MW: Antiretroviral Therapy Coverage: % of People Living with HIV data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Malawi – Table MW.World Bank.WDI: Health Statistics. Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.; ; UNAIDS estimates.; Weighted average;

People aged 15 to 59 years seen at HIV services in the UK, expressed as a rate per 1,000 population.Data is presented by area of residence, and exclude people diagnosed with HIV in England who are resident in Wales, Scotland, Northern Ireland or abroad.RationaleThe geographical distribution of people seen for HIV care and treatment is not uniform across or within regions in England. Knowledge of local diagnosed HIV prevalence and identification of local risk groups can be used to help direct resources for HIV prevention and treatment.In 2008, http://www.bhiva.org/HIV-testing-guidelines.aspx recommended that Local Authority and NHS bodies consider implementing routine HIV testing for all general medical admissions as well as new registrants in primary care where the diagnosed HIV prevalence exceeds 2 in 1,000 population aged 15 to 59 years.In 2017, guidelines were updated by https://www.nice.org.uk/guidance/NG60 which is co-badged with Public Health England. This guidance continues to define high HIV prevalence local authorities as those with a diagnosed HIV prevalence of between 2 and 5 per 1,000 and extremely high prevalence local authorities as those with a diagnosed HIV prevalence of 5 or more per 1,000 people aged 15 to 59 years.When this is applied to national late HIV diagnosis data, it shows that two-thirds of late HIV diagnoses occur in high-prevalence and extremely-high-prevalence local authorities. This means that if this recommendation is successfully applied in high and extremely-high-prevalence areas, it could potentially affect two-thirds of late diagnoses nationally.Local authorities should find out their diagnosed prevalence published in UKHSA's http://fingertips.phe.org.uk/profile/sexualhealth , as well as that of surrounding areas and adapt their strategy for HIV testing using the national guidelines.Commissioners can use these data to plan and ensure access to comprehensive and specialist local HIV care and treatment for HIV diagnosed individuals according to the http://www.medfash.org.uk/uploads/files/p17abl6hvc4p71ovpkr81ugsh60v.pdf and http://www.bhiva.org/monitoring-guidelines.aspx .Definition of numeratorThe number of people (aged 15 to 59 years) living with a diagnosed HIV infection and accessing HIV care at an NHS service in the UK and who are resident in England.Definition of denominatorResident population aged 15 to 59.The denominators for 2011 to 2023 are taken from the respective 2011 to 2023 Office for National Statistics (ONS) revised population estimates from the 2021 Census.Further details on the ONS census are available from the https://www.ons.gov.uk/census .CaveatsData is presented by geographical area of residence. Where data on residence were unavailable, residence have been assigned to the local health area of care.Every effort is made to ensure accuracy and completeness of the data, including web-based reporting with integrated checks on data quality. The overall data quality is high as the dataset is used for commissioning purposes and for the national allocation of funding. However, responsibility for the accuracy and completeness of data lies with the reporting service.Data is as reported but rely on ‘record linkage’ to integrate data and ‘de-duplication’ to prevent double counting of the same individual. The data may not be representative in areas where residence information is not known for a significant proportion of people accessing HIV care.Data supplied for previous years are updated on an annual basis due to clinic or laboratory resubmissions and improvements to data cleaning. Data may therefore differ from previous publications.Values are benchmarked against set thresholds and categorised into the following groups: <2 (low), 2 to 5 (high) and≥5 (extremely high). These have been determined by developments in national testing guidelines.The data reported in 2020 and 2021 is impacted by the reconfiguration of sexual health services during the national response to COVID-19.

United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.130 Ratio in 2020. This records an increase from the previous number of 0.120 Ratio for 2019. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.020 Ratio from Dec 1990 (Median) to 2020, with 31 observations. The data reached an all-time high of 0.130 Ratio in 2020 and a record low of 0.010 Ratio in 2004. United Arab Emirates AE: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United Arab Emirates – Table AE.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Cuba CU: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.600 % in 2022. This stayed constant from the previous number of 0.600 % for 2021. Cuba CU: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.200 % from Dec 1990 (Median) to 2022, with 33 observations. The data reached an all-time high of 0.600 % in 2022 and a record low of 0.100 % in 2003. Cuba CU: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cuba – Table CU.World Bank.WDI: Social: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.;UNAIDS estimates.;Weighted average;

As of 2024, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.8 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.5 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by South Africa and Mozambique. However, South Africa had the highest total number of new HIV infections in 2024, with around 170,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the eighth leading cause of death in Africa, accounting for around 4.6 percent of all deaths. In 2024, South Africa and Mozambique were the countries with the highest number of AIDS-related deaths worldwide, with 53,000 and 44,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years, and now up to 94 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 81 percent of people who are HIV positive in South Africa receiving ART and only 34 percent in the Congo.

According to Cognitive Market Research, the global HIV drugs market size was USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.

Market Dynamics of HIV drugs Market

Key Drivers for HIV drugs Market

Rising number of HIV-positive individuals to Increase the Demand Globally

The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.

Innovations in HIV diagnostic tools to Propel Market Growth

The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.

Restraint Factor for the HIV drugs Market

High cost of HIV treatment to Limit the Sales

The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.

Impact of Covid-19 on the HIV drugs Market

The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market

HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased awaren...

According to Cognitive Market Research, the global HIV Diagnostics market size is USD 4158.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 10.90% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 1663.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1247.46 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 956.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031. Latin America had a market share of more than 5% of the global revenue with a market size of USD 207.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 83.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031. Consumables held the highest HIV Diagnostics market revenue share in 2024. Market Dynamics of HIV Diagnostics Market Key Drivers for HIV Diagnostics Market Increasing Prevalence of Sexually Transmitted Disease to Increase the Demand Globally Throughout the many decades of the HIV pandemic, the number of infected individuals is continually rising. The socioeconomic variables driving this continuous increase also suggest that preventative measures have not been successful. Even though many of these infections are preventable, there are an estimated 20 million new cases of STDs in the US each year, and the rate is still rising. Moreover, there are over 1.2 million HIV-positive individuals residing in the United States. Attempts to encourage testing and screening for sexually transmitted infections can ascertain an individual's likelihood of acquiring one and help those who already have one receive treatment, so enhancing their health and lowering the danger of HIV spreading to others. Approximately 38.4 million people worldwide were HIV positive in 2021. Among these, women and girls made up nearly 54%. Rising Initiatives by Global Agencies to Propel Market Growth HIV is among the world's most important public health concerns. As a result, there is a global commitment to stopping new HIV infections and giving everyone on the planet access to HIV therapy. WHO recommends testing for HIV to anyone who might be at risk. The World Bank was a leader in global financing for HIV/AIDS in the early phases of the pandemic and has contributed US$4.6 billion to programs related to the illness since 1989. Because of assistance from the Bank—more precisely, through the International Development Association—for 1,500 counseling and testing centers, about 7 million people have had HIV tests. Restraint Factor for the HIV Diagnostics Market Lack of Healthcare Infrastructure and Awareness to Limit the Sales A proper infrastructure for healthcare delivery is lacking in many areas, especially in poor nations, which makes it difficult to provide diagnostic services. This covers concerns with the supply chain, inadequate laboratory facilities, and skilled staff. It might be particularly difficult to access diagnostic services in rural and isolated places due to a lack of healthcare facilities and inadequate transportation infrastructure. Furthermore, HIV diagnosis rates are lower in the developing Asia-Pacific, Middle East, and African regions. These areas require a sufficient number of diagnostic facilities. Additionally, the diagnosis process needs to be explained to the majority of patients, which restricts market growth in these areas. Impact of Covid-19 on the HIV Diagnostics Market The COVID-19 pandemic has had a significant impact on the HIV diagnostics market, both in terms of challenges and opportunities. There was a decrease in HIV testing and diagnostic services during the pandemic as a result of the extensive healthcare resources being redirected to handle COVID-19. Some facilities were converted to provide COVID-19 treatment, and clinics and labs had a staffing crisis. Reduced HIV testing rates were the outcome of routine and community-based HIV testing programs being frequently halted to stop the spread of COVID-19. The adoption of telemedicine and remote healthcare services was expedited by the epidem...

BackgroundSince the first HIV/AIDS case appeared in 1980s, HIV/AIDS has been the focus of international attention. As a major public health problem, there are epidemiological uncertainties about the future of HIV/AIDS. It is important to monitor the global statistics of HIV/AIDS prevalence, deaths, disability adjusted life years (DALYs), and risk factors for adequate prevention and control.MethodsThe Global Burden of Disease Study 2019 database was used to analyze the burden of HIV/AIDS in 1990–2019. By extracting global, regional, and national data on HIV/AIDS prevalence, deaths, and DALYs, we described the distribution by age and sex, explored the risk factors, and analyzed the trends in HIV/AIDS.ResultsIn 2019, there were 36.85 million HIV/AIDS cases (95% UI: 35.15–38.86 million), 863.84 thousand deaths (95% UI: 78.61–99.60 thousand), and 47.63 million (95% UI: 42.63–55.65 million) DALYs. The global age-standardized HIV/AIDS prevalence, death, and DALY rates were 454.32 (95% UI: 433.76–478.59), 10.72 (95% UI: 9.70–12.39), and 601.49 (95% UI: 536.16–703.92) per 100,000 cases, respectively. In 2019, the global age-standardized HIV/AIDS prevalence, death, and DALY rates increased by 307.26 (95% UI: 304.45–312.63), 4.34 (95% UI: 3.78–4.90), and 221.91 (95% UI: 204.36–239.47) per 100,000 cases, respectively, compared to 1990. Age-standardized prevalence, death, and DALY rates decreased in high sociodemographic index (SDI) areas. High age-standardized rates were observed in low sociodemographic index areas, while low age-standardized rates were observed in high sociodemographic index areas. In 2019, the high age-standardized prevalence, death, and DALY rates were predominant in Southern Sub-Saharan Africa, and global DALYs peaked in 2004 and subsequently decreased. The highest global HIV/AIDS DALYs were in the 40–44 age group. The main risk factors affecting HIV/AIDS DALY rates included behavioral risks, drug use, partner violence, and unsafe sex.ConclusionsHIV/AIDS disease burden and risk factors vary by region, sex, and age. As access to health care increases across countries and treatment for HIV/AIDS infection improves, the HIV/AIDS disease burden is concentrated in areas with low SDIs, particularly in South Africa. Regional differences should be fully considered to target optimal prevention strategies and treatment options based on risk factors.